Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.26)
# 390
Out of 5,050 analysts
79
Total ratings
53.57%
Success rate
17.17%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $60.16 | +32.98% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.13 | +133.92% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $15.24 | +18.11% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $18.18 | +87.02% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $38.25 | +43.79% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $24.54 | +30.40% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $152.37 | +21.41% | 2 | Apr 24, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $61.80 | -19.09% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $17.17 | +191.21% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $103.14 | +21.19% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $51.46 | +104.04% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $657.53 | +78.70% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $86.55 | -1.79% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $30.63 | +187.30% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $155.51 | +77.48% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.09 | +755.75% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $320.20 | -27.55% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $105.98 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $118.84 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $32.89 | -36.15% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.99 | +283.97% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.83 | +2,208.40% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.25 | +700.00% | 1 | Feb 14, 2018 |
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $60.16
Upside: +32.98%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.13
Upside: +133.92%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $15.24
Upside: +18.11%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $18.18
Upside: +87.02%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $38.25
Upside: +43.79%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $24.54
Upside: +30.40%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $152.37
Upside: +21.41%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $61.80
Upside: -19.09%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $17.17
Upside: +191.21%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $103.14
Upside: +21.19%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $51.46
Upside: +104.04%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $657.53
Upside: +78.70%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $86.55
Upside: -1.79%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $30.63
Upside: +187.30%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $155.51
Upside: +77.48%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.09
Upside: +755.75%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $320.20
Upside: -27.55%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $105.98
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $118.84
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $32.89
Upside: -36.15%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.99
Upside: +283.97%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.83
Upside: +2,208.40%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.25
Upside: +700.00%